Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna's stock faces volatility despite insider buying and cancer vaccine progress. Patent battles and revenue shifts create uncertainty. A comprehensive analysis.
Moderna faces patent lawsuits and funding uncertainty despite UK approval of its RSV vaccine. A deep dive into challenges and opportunities.
Moderna faces funding scrutiny and rising mRNA competition. Cost cuts, political shifts, and pipeline updates shape its future. Analyst outlook mixed.
Moderna is navigating a post-pandemic market with cost cuts and pipeline diversification amid competition and government funding uncertainties. Key developments and strategic implications analyzed.
Analyzing Moderna's (MRNA) pipeline, including RSV and cancer vaccines, financial strategies, and international market performance. Get the latest insights on MRNA stock and industry trends.
Moderna (MRNA) navigates a dynamic market influenced by emerging diseases, competition, and analyst views. Pipeline progress and revenue are key.
Moderna faces mixed analyst sentiment amid pipeline advancements and financial adjustments, influencing investor strategies.
Moderna faces mixed investor sentiment as pipeline prospects compete with declining COVID-19 vaccine revenue, shaping intraday market dynamics and future outlook.
A comprehensive analysis of Moderna’s mixed Q4 2024 results, cost-cutting, and diversified pipeline amid declining COVID-19 vaccine sales.
Moderna's Q4 2024 earnings beat revenue estimates amid higher losses and active pipeline diversification, revealing both challenges and opportunities.